Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
Open Access
- 16 January 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 110 (4), 984-990
- https://doi.org/10.1038/bjc.2013.815
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Preoperative Plasma Hyperfibrinogenemia is Predictive of Poor Prognosis in Patients with Nonmetastatic Colon CancerAnnals of Surgical Oncology, 2013
- The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trialBritish Journal of Cancer, 2010
- Plasma Fibrinogen Levels and Prognosis in Patients with Ovarian Cancer: A Multicenter StudyThe Oncologist, 2009
- Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEuropean Respiratory Journal, 2009
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Fibrin structure and wound healingJournal of Thrombosis and Haemostasis, 2006
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.British Journal of Cancer, 1998
- A proposed new International TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest GroupLung Cancer, 1996
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957